Anesthesiology Research Analysis
May’s anesthesiology research emphasized translational non‑opioid analgesia, hemodynamic safety during high‑risk induction, and pragmatic blood conservation in hepatic surgery. Rigorous randomized trials supported cipepofol for induction in severe aortic stenosis and validated sugammadex dosing in infants under two years. Consensus work clarified ARDS definitions and prioritized subphenotyping, while decision-support tools continued to improve airway planning. Together, these advances point to s
Summary
May’s anesthesiology research emphasized translational non‑opioid analgesia, hemodynamic safety during high‑risk induction, and pragmatic blood conservation in hepatic surgery. Rigorous randomized trials supported cipepofol for induction in severe aortic stenosis and validated sugammadex dosing in infants under two years. Consensus work clarified ARDS definitions and prioritized subphenotyping, while decision-support tools continued to improve airway planning. Together, these advances point to safer inductions, targeted perioperative strategies, and reduced reliance on opioids.
Selected Articles
1. Arrestin-biased allosteric modulator of neurotensin receptor 1 alleviates acute and chronic pain.
Preclinical identification of SBI-810, a β-arrestin–biased positive allosteric modulator of NTSR1, demonstrated potent analgesia across postoperative, inflammatory, and neuropathic rodent models with favorable behavioral effects and mechanistic specificity.
Impact: Introduces a mechanistically distinct, non-opioid analgesic with central and peripheral actions and reduced opioid-like liabilities, representing a strong translational candidate.
Clinical Implications: Supports IND-enabling studies and early-phase trials; if efficacy translates to humans, perioperative pain control could shift away from opioids with fewer adverse effects.
Key Findings
- Robust analgesia across multiple pain models via systemic and local routes.
- Analgesia required NTSR1 and β-arrestin-2, suppressing NMDA/ERK and reducing Nav1.7 surface expression.
- Reduced opioid reward, constipation, and withdrawal-like behaviors in behavioral assays.
2. Sugammadex for Reversal of Neuromuscular Blockade in Neonates and Infants Less than 2 Years Old: Results from a Phase IV Randomized Clinical Trial.
A multicenter phase IV RCT (n=138) showed 2 mg/kg sugammadex rapidly reverses moderate block vs neostigmine and 4 mg/kg reverses deep block in infants under two years with comparable safety.
Impact: Closes a critical pediatric dosing gap and supports confident use of sugammadex in neonates and infants.
Clinical Implications: Consider 2 mg/kg for moderate and 4 mg/kg for deep block reversal in infants; maintain vigilance for rare hypersensitivity via postmarketing surveillance.
Key Findings
- 2 mg/kg sugammadex reversed moderate block faster than neostigmine (median 1.4 vs 4.4 min).
- 4 mg/kg achieved rapid reversal from deep block (median 1.1 min).
- No drug-related serious adverse events or hypersensitivity reported.
3. Hemodynamic Impact of Cipepofol vs Propofol During Anesthesia Induction in Patients With Severe Aortic Stenosis: A Randomized Clinical Trial.
A randomized trial in severe aortic stenosis (TAVR) patients showed cipepofol reduced postinduction MAP deficit, hypotension incidence, and norepinephrine needs compared with propofol at matched depth.
Impact: Offers actionable induction-agent choice to improve hemodynamic safety in a high-risk cardiac cohort.
Clinical Implications: Consider cipepofol for severe AS induction to mitigate hypotension, pending multicenter outcome confirmation and availability.
Key Findings
- Smaller MAP deficit AUC in first 15 minutes postinduction with cipepofol.
- Lower incidence of postinduction hypotension (70.5% vs 88.5%).
- Reduced norepinephrine use at matched BIS levels.
4. Defining and subphenotyping ARDS: insights from an international Delphi expert panel.
An international four-round Delphi established a consensus conceptual model and essential components for ARDS definitions and prioritized subphenotyping to address heterogeneity and guide future trials.
Impact: Provides foundational harmonization that will influence diagnosis, stratification, and phenotype-guided therapies across critical care.
Clinical Implications: Adopt the consensus framework in research/registries and accelerate biomarker and imaging-based subphenotyping.
Key Findings
- Consensus conceptual model and defining components for ARDS across clinical and research contexts.
- Endorsement of advancing subphenotyping to mitigate heterogeneity.
- Rigorous multi-round anonymous Delphi with diverse global experts.
5. Impact of Hypovolemic Phlebotomy with Low Central Venous Pressure on Intraoperative Blood Loss in Open Liver Resection: A Double-Blind Randomized Controlled Trial.
A double-blind RCT (n=100) showed protocolized hypovolemic phlebotomy expedites low CVP, reduces transection blood loss, and improves bleeding scores without increasing transfusions or complications.
Impact: Offers a controllable intraoperative maneuver with measurable reductions in bleeding during open hepatectomy.
Clinical Implications: Surgical–anesthesia teams can adopt controlled phlebotomy protocols with close hemodynamic monitoring to achieve low CVP and reduce bleeding.
Key Findings
- Reduced parenchymal transection blood loss (median 300 vs 500 mL).
- Faster achievement of low CVP (~50 vs 107.5 minutes).
- Independent protection against >500 mL blood loss (AOR 0.19).